Exendin-4 ameliorates renal ischemia-reperfusion injury in the rat

Journal of Surgical Research

Volumn 185, Issue 2, 2013, Pages 825-832

  Yang, Hua ^a   Li, Heng ^a   Wang, Zhendi ^a   Shi, Yuxiang ^b   Jiang, Guosong ^a   Zeng, Fuqing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CENTRAL HOSPITAL OF WUHAN   (China)

Author keywords

Apoptosis; Caspase 3; Exendin 4; Glucagon like peptide 1; Heme oxygenase 1; HO 1; Macrophage; Male rats; Renal ischemia reperfusion

Indexed keywords

CASPASE 3; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HEME OXYGENASE 1; MESSENGER RNA; ANTIDIABETIC AGENT; CREATININE; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; PEPTIDE; VENOM; GLUCAGON LIKE PEPTIDE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY TUBULE CELL; MALE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; REPERFUSION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; TISSUE PREPARATION; WESTERN BLOTTING; AGONISTS; ANIMAL; BLOOD; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENETICS; KIDNEY DISEASES; MACROPHAGE; METABOLISM; PATHOPHYSIOLOGY; DRUG EFFECT; DRUG POTENTIATION; EXENDIN-4; HO-1; KIDNEY DISEASE; MALE RATS; RENAL ISCHEMIA-REPERFUSION;

ANIMALS; APOPTOSIS; CREATININE; DISEASE MODELS, ANIMAL; HEME OXYGENASE-1; HYPOGLYCEMIC AGENTS; KIDNEY DISEASES; MACROPHAGES; MALE; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; REPERFUSION INJURY; RNA, MESSENGER; VENOMS;

APOPTOSIS; CASPASE-3; EXENDIN-4; GLUCAGON-LIKE PEPTIDE-1; HEME OXYGENASE-1; HO-1; MACROPHAGE; MALE RATS; RENAL ISCHEMIA-REPERFUSION;

EID: 84891682227     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2013.06.042     Document Type: Article

References (37)

1. Lameire N, Van BW, Vanholder R. Acute renal failure. Lancet 2005;365:417.
2. Jo SK, Sung SA, Cho WY, et al. Macrophages contribute to the initiation of ischaemic acute renal failure in rats. Nephrol Dial Transpl 2006;21:1231.
3. Wang Z, Schley G, Tü rkoglu G, et al. The protective effect of prolyl-hydroxylase inhibition against renal ischaemia requires application prior to ischaemia but is superior to EPO treatment. Nephrol Dial Transpl 2012;27:929.
4. Bernhardt WM, Câmpean V, Kany S, et al. Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J Am Soc Nephrol 2006;17:1970.
5. Villanueva S, Céspedes C, González AA, et al. Effect of ischemic acute renal damage on the expression of COX-2 and oxidative stress-related elements in rat kidney. Am J Physiol Ren Physiol 2007;292:F1364.
6. Yu SJ, Oh DJ, Yu SH. The investigation of macrophage infiltration in the early phase of ischemic acute renal failure in mice. Korean J Intern Med 2008;23:64.
7. Abraham NG, Cao J, Sacerdoti D, et al. Heme oxygenase: the key to renal function regulation. Am J Physiol Ren Physiol 2009;297:F1137.
8. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131.
9. Thum A, Hupe-Sodmann K, Goke R, et al. Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and-4. Exp Clin Endocrinol Diabetes 2002;110:113.
10. Chen J, Couto FM, Minn AH, et al. Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun 2006;346:1067.
11. Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003;278:471.
12. Oeseburg H, de Boer RA, Buikema H, et al. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 2010;30:1407.
13. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008;146:243.
14. Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54:146.
15. Shimizu H, Takahashi T, Suzuki T, et al. Protective effect of heme oxygenase induction in ischemic acute renal failure. Crit Care Med 2000;28:809.
16. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995;358:219.
17. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996;137:2968.
18. Parkes D, Jodka C, Smith P, et al. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res 2001;53:260.
19. Guan X, Dei-Anane G, Liang R, et al. Donor preconditioning with taurine protects kidney grafts from injury after experimental transplantation. J Surg Res 2008;146:127.
20. Bonventre JV. Kidney ischemic preconditioning. Curr Opin Nephrol Hypertens 2002;11:43.
21. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696.
22. Holst JJ. Glucagon-like peptide-1: from extract to agent: the Claude Bernard Lecture, 2005. Diabetologia 2006;49:253.
23. Matsubara M, Kanemoto S, Leshnower BG, et al. Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury. J Surg Res 2011;165:38.
24. Lee CH, Yan B, Yoo KY, et al. Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia. J Neurosci Res 2011;89:1103.
25. Park CW, Kim HW, Ko SH, et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 2007;18:1227.
26. During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003;9:1173.
27. Kirkby KA, Adin CA. Products of heme oxygenase and their potential therapeutic applications. Am J Physiol Ren Physiol 2006;290:F563.
28. Lee PC, Ho IC, Lee TC. Oxidative stress mediates sodium arsenite-induced expression of heme oxygenase-1, monocyte chemoattractant protein-1, and interleukin-6 in vascular smooth muscle cells. Toxicol Sci 2005;85:541.
29. Ryter SW, Choi AM. Heme oxygenase-1: redox regulation of a stress protein in lung and cell culture models. Antioxid Redox Signal 2005;7:80.
30. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009;58:975.
31. Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell 1997;91:443.
32. Lakhani SA, Masud A, Kuida K, et al. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 2006;311:847.
33. Faubel S, Edelstein CL. Caspases as drug targets in ischemic organ injury. Curr Drug Targets Immune Endocr Metabol Disord 2005;5:269.
34. Kunduzova OR, Escourrou G, Seguelas MH, et al. Prevention of apoptotic and necrotic cell death, caspase-3 activation, and renal dysfunction by melatonin after ischemia/reperfusion. FASEB J 2003;17:872.
35. Mortensen J, Shames B, Johnson CP, et al. MnTMPyP, a superoxide dismutase/catalase mimetic, decreases inflammatory indices in ischemic acute kidney injury. Inflamm Res 2011;60:299.
36. Segerer S, Nelson PJ, Schlöndorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000;11:152.
37. Furuichi K, Wada T, Iwata Y, et al. CCR2 signaling contributes to ischemiaereperfusion injury in kidney. J Am Soc Nephrol 2003;14:2503.